Vaccine Problems, PTV News: Mar 24, 2010

Episode Loading...

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Vaccine Problems, PTV News: Mar 24, 2010
Released on: March 24, 2010. © PharmaVentures Ltd
Visitors: You are watching a 1 minute preview.
Share/save this page:
Follow us:
  • Summary
  • Transcript
  • Participants
  • Company
Merck Serono suspends trials of Stimuvax cancer vaccine after encephalitis case
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Josef Walker
Senior Analyst

Josef has conducted in-depth projects for numerous companies from the biotech, pharmaceutical and medical device sectors and has extensive experience in deal and trend analysis, market research, benchmarking, transactions, litigation support and pipeline assessments. Josef has a degree in Molecular Biology from the University of Leicester and a PhD in Molecular Immunology from University College London. He previously engaged in postdoctoral research on the interactions between human dendritic cells and type I interferons at the Edward Jenner Institute for Vaccine Research.
PharmaVentures Ltd
PharmaVentures is a company that has proven success in deals and alliances.

PharmaVentures offers:

• Over 18 years of healthcare industry experience

• Experience gained from working with in excess of 1000 clients in 38 countries, and conducting more than 450 assignments

• Over 40 specialist advisors, analysts and researchers

• Skills honed in many countries - 80% of its business comes from outside the UK
Merck Serono
Merck Serono (EMD Serono in the United States and Canada) is a pharmaceutical company headquartered in Geneva, Switzerland.[1] In September 2006, Merck KGaA announced its intent to purchase the majority of Serono shares from Ernesto Bertarelli and the Bertarelli family. The Merck-Serono merger was announced on September 21, 2006. Merck KGaA and Serono operated as distinct entities until at least January 2007. As of January 5, 2007, Merck held the majority shares of Serono. The new company is called Merck Serono International S.A.
Oncothyreon is a biotechnology company dedicated to the development of oncology products that can improve the lives and outcomes of cancer patients. The firm is currently developing multiple therapeutic candidates designed to target cancer in specific and effective ways. Its pipeline includes both synthetic vaccines and small molecules for a variety of cancer indications.